Report : North America Corneal Transplantation Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type [Penetrating Keratoplasty, Descemet Membrane Endothelial Keratoplasty (DMEK), Descemet Stripping Endothelial Keratoplasty (DSEK), Corneal Limbal Stem Cell Transplant, and Others], Indication (Fungal Corneal Ulcer, Fuchs Dystrophy, Keratoconus, Keratitis, and Others), and End User (Hospitals, Eye Clinic, and Ambulatory Surgical Centers)

Penetrating Keratoplasty Segment to Dominate North America Corneal Transplantation Market During 2021–2028

According to a new market research study on “North America Corneal Transplantation Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Type, Indication, and End User” is expected to reach US$ 318.25 million by 2028 from US$ 207.03 million in 2021. The market is estimated to grow at a CAGR of 6.3% from 2021 to 2028. The report provides trends prevailing in the North America corneal transplantation market along with the drivers and restraints pertaining to the market growth. Growing incidence of eye diseases and rise in geriatric population are the major factor driving the growth of the North America corneal transplantation market. However, complications associated with corneal transplantation and shortage of donor corneas hinders the growth of North America corneal transplantation market.  

The North America corneal transplantation market is segmented based on type, indication, end user, and country. Based on type, the North America corneal transplantation market is segmented into penetrating keratoplasty, descemet membrane endothelial keratoplasty (DMEK), descemet stripping endothelial keratoplasty (DSEK), corneal limbal stem cell transplant, and others. The penetrating keratoplasty segment dominated the North America corneal transplantation market in 2020 and descemet membrane endothelial keratoplasty (DMEK) segment is expected to be fastest growing during forecast period. Based on indication, the North America corneal transplantation market is segmented into fungal corneal ulcer, fuchs dystrophy, keratoconus, keratitis, and others. The fuchs dystrophy segment dominated the North America corneal transplantation market in 2020 and same segment is expected to be fastest growing during forecast period. Based on end user, the North America corneal transplantation market is segmented into hospitals, eye clinic, and ambulatory surgical centers. The hospitals segment dominated the North America corneal transplantation market in 2020 and ambulatory surgical centers segment is expected to be fastest growing during forecast period. Based on country, the North America corneal transplantation market has been segmented into the US, Canada, and Mexico.     

Alcon Inc.; Aurolab; Cornea Biosciences, Inc.; CorneaGen; Corneat Vision; Florida Lions Eye Bank; Keramed, Inc.; Lifeline Scientific, Inc.; and Massachusetts Eye and Ear are among the leading companies in the North America corneal transplantation market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2019, CorNeat Vision, an Israeli ophthalmic medical solution company, announced that it has completed the pre-clinical stage of its revolutionary cornea implant (CorNeat KPro / Keratoprosthesis) and the first synthetic, non-degradable scleral patch (CorNeat EverPatch).   

Contact Us
Contact Person: Sameer Joshi 
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com
  

 

Download Free PDF Brochure